ABSTRACT

INTRODUCTION

Previous Work

Aim

METHODOLOGIES

The first and the most common therapy that is used to treat cancer patients is radiotherapy, which uses the UV radiations to degenerate the cancer cells, but the problem is not just kills the cancer cell but also the normal cells thus, an healthy alternative was required to treat the cancer patients and Chemotherapy comes into action. Chemotherapy is a type of cancer treatment therapy that follows standardized regimen using one or many anti-cancer drugs to treat the cancer cells. This therapy is effective because it puts aggressive constrains on cancerous cells from growing, mutating, and breaking into more cells.

To decipher the mechanism of drug administration of Chemotherapy, the therapy can be considered as blend of two approaches namely, Pharmacokinetic (PK) and Pharmacodynamic (PD). In this therapy, the pharmacokinetic model is defined as the drug dosage administration with respect to the models built and the dosage considered. On the other hand, the model of pharmacodynamic is coined at the analysis of the effect of drug and the mechanism of drug action. These two models basically form a simultaneous compartment model which can explained as, when the drug is taken, the PK model is considered for examination and when the drug starts it’s action on the body of the patient or on the cancer cells, the PD model takes the lead.

------------------------------------ 1

1. Design and building framework for modelling and optimization for medical/ healthcare system.
2. Components of framework:
   1. Build models, optimize parameters, and test build models.
   2. Simulating the biological mechanism for the models and optimization
   3. Collecting significant patient-specific features to find the outcome.
   4. Hybrid method
3. Benefits of building a model for bio-medical: analysis over distinct values of scales and influencing factors (i.e., clearance, absorption rate, dose, time interval, etc). [1]
4. Understanding the influencing of changing parameters based on observations and interpretations to analysis the behaviour and biological of the characteristics within the body. [2], [3], [4], [5]
5. It is complex to decipher the impact of dose within a biological body and the further implications but with the study of personalized medication possible from getting deeper insights of protein and molecules in a large-scale help in gaining precise, cost-effective, and patient-specific diagnostic details. [6].
6. Challenges:
   1. The authenticity and the validity of the methodologies used.
   2. Incorporation of 3 vital elements:
      1. Patient-specific information
      2. Disease-specific information
      3. Building adaptive/ dynamic model for the patient of better treatment.

------------------------------- 1

Ordinary Differential Equations

------------------------------- 1

When we model or form differential equations for a cell population that contains the degrading cell and the healthy cells that can transition towards unhealthy cell, it is known as delay differential equation with the change rate being dependent on life cycle time for each cell. [9]

With context to the work of [10], [11], [12] gave a more detailed balanced model based on the multi-staging. The susceptibility and the growth of tumour cells is influenced by the metabolism of cells existing in the cancer spread region, which is modelled using an advanced analysis and framing the model mathematically based on the metabolism of cell as given by [13]. And it helps to find the precise correlation for the cell cycle using the process of selection, detection, and quantification.

For the oral administration with the PK model using the ODE, following are the equations:

Equation1: shows the rate of change in the amount of Imatinib in gastrointestinal track at time is given as:

and Equation 2: illustrates the rate of change in the amount Imatinib in blood at time is represented as:

In equation 1, is the amount of Imatinib in the gastrointestinal track at time t, ka is a rate constant or the first order absorption or simply, the rate of absorption and negative sign here, indicates the decrease in the amount of drug with time as it starts dissolving in the gastrointestinal track.

In equation 2, is the amount of Imatinib in the blood at time t with volume v and the rate constant CL also known as clearance which determines the rate of elimination of drug. Thus, the second equation can also be framed as the rate of change in amount of Imatinib in gastrointestinal track being equal to the difference between the rate at which it is absorbed from the gastrointestinal track and the rate at which is it removed. In this equation, the value of is known as the concentration of Imatinib in blood.

For the analysis, the initial value of in the equation 1 is the product of D i.e., drug dose and f i.e., bioavailability where the bioavailability determines the proportion of the drug that goes into circulation (for initial analysis, value of f is 1 which signifies a complete circulation) and D is the drug dose given to a cancer patient (initially, a random value of D is taken to be 400 mg). While for equation 2, the initial value of is 0 which explains the fact that since, the drug dosage is not taken, the rate of elimination of drug is 0.

------------------------------- 1

Optimization

------------------------------- 1

Chemotherapy Optimization help in the acquaintance with the optimized structure of the PK model assists in achieving a patient-specific and scheduled dose interval. [7]

So, basically, the Pharmacokinetics (PK) model determines the propagation and the metamorphosis once the drug – a specific concentration of drug - reaches the blood stream, different organ system with different absorption rate (f) and thus, is based on mass balance. And due to generation, degradation, and regenerations of cells, it becomes crucial in Chemotherapy to reflect the same in the drug equation with point of action.

\*Pharmacodynamic (PD) model.

It is paramount to balance the proportion of drug impact on the cells at the time of degeneration of healthy cells and that of cancer cells thus, based on the profile for the corresponding concentration of the drug, the inputs are feed to the PD model from the PK model. Therefore, for modelling the kinetic of the cells, a sequence of Ordinary Differential Equations is used [8] as showed from equations 1 and 2. And once the equations and designed and built

\*Get images: Personalized Chemotherapy Protocol

To have optimal patient specific model, the used cost function is the integral of the Euclidean distance between the optimal target concentration and the steady state concentration with time, the relation is represented as by:

Where, is the penalty function also known as the cost function, is the concentration of Imatinib, is the target concentration with t1 as the initial observation time and t2 as the final observation time.

----------------------------- 1

DATA

1. [12] showed that the kinetic of a cell is a vital component to measure for a complicated and complex analysis and it focussed on
   1. Span of a cell life cycle before regenerating or degrading.
   2. Influencing factors of the surrounding environment that tend to affect the metabolism of leukaemia cells.

REFERENCES

----------------------------1

[1] Hall et al., 2011 C. Hall, E. Lueshen, A. Mošat’, A.A. Linninger Interspecies scaling in pharmacokinetics: a novel whole-body physiologically based modeling framework to discover drug biodristribution mechanisms in vivo J Pharm Sci, 101 (3) (2011), pp. 1221-1241

[2] Androulakis, 2014 I.P. Androulakis A chemical engineer's perspective on health and disease Comput Chem Eng, 71 (2014), pp. 665-671

[3] Chen et al., 2012 T. Chen, N.F. Kirkby, R. Jena Optimal dosing of cancer chemotherapy using model predictive contro and moving horizon state/parameter Estimation Comput Methods Programs Biomed, 108 (3) (2012), pp. 973-983

[4] Harrold and Parker, 2009 J.M. Harrold, R.S. Parker Clinically relevant cancer chemotherapy dose scheduling via mixed-integer optimization Comput Chem Eng, 33 (12) (2009), pp. 2042-2054

[5] Ho et al., 2013 T. Ho, G. Clermont, R.S. Parker A model of neutrophil dynamics in response to inflammatory and cancer chemotherapy challenges Comput Chem Eng, 51 (2013), pp. 187-196

[6] Saha et al., 2014 R. Saha, A. Chowdhury, C.D. Maranas Recent Advances in the reconstruction of metabolic models and integration of omics data Curr Opin Biotechnol, 29 (2014), pp. 39-45

[7] Pefani et al., 2013 E. Pefani, N. Panoskaltsis, A. Mantalaris, M.C. Georgiadis, E.N. Pistikopoulos Design of optimal patient-specific chemotherapy protocols for the treatment of acute myeloid leukemia (AML) Comput Chem Eng, 57 (2013), pp. 187-195

[8] Pefani et al., 2014 E. Pefani, N. Panoskaltsis, A. Mantalaris, M.C. Georgiadis, E.N. Pistikopoulos Chemotherapy drug scheduling for the induction treatment of patients diagnosed with acute myeloid leukemia Trans Biomed Eng J, 61 (7) (2014), pp. 2049-2056

[9] Basse et al., 2003 B. Basse, B.C. Baguley, E.S. Marshall, W.R. Joseph, B.V. Brunt, G. Wake A mathematical model for analysis of the cell cycle in cell lines derived from human tumours Math Biol, 47 (2003), pp. 295-312

[10] García Münzer et al., 2013 D.G. García Münzer, M. Kostoglou, M. Georgiadis, E.N. Pistikopoulos, A. Mantalaris Developing a cyclin blueprint as a tool for mapping the cell cycle in GS-NS0 Biochem Eng J, 81 (2013), pp. 97-107

[11] García Münzer et al., 2014 D.G. García Münzer, M. Kostoglou, M.C. Georgiadis, E.N. Pistikopoulos, A. Mantalaris A cyclin distributed cell cycle model in GS-NS0 J.J. Kleměs, P.S. Varbanov, P.Y. Liew (Eds.), 24th European symposium on computer aided process engineering., vol. 33, Computer-Aided Chemical Engineering, Budapest, Hungary (2014), pp. 19-24

[12] Fuentes-Garí et al., 2015 M. Fuentes-Garí, R. Misener, D.G. García-Münzer, E. Velliou, M. Kostoglou, M. Georgiadis, N. Panoskaltsis, et al. A mathematical model of sub-population kinetics for the deconvolution of leukemia heterogeneity J R Soc Interface (2015)

[13] Kiparissides et al., 2011 A. Kiparissides, M. Koutinas, C. Kontoravdi, A. Mantalaris, E.N. Pistikopoulos ‘Closing the loop’ in biological systems modeling—from the in silico to the in vitro Automatica, 47 (6) (2011), pp. 1147-1155

----------------------------1